Pharmaceutical companies today face a critical question at the earliest stages of pipeline development: should they pursue a first-in-class molecule targeting a novel biological pathway, or develop a best-in-class therapy that improves upon existing treatments?
This strategic decision shapes not only scientific direction but also financial risk, regulatory pathways, intellectual property positioning, and long-term market impact. At World BI, through the Drug Discovery Innovation Programme, we consistently explore how such high-level strategic decisions define the future of pharmaceutical innovation. The debate between first-in-class and best-in-class therapies is not merely scientific, it represents the evolving philosophy of modern drug discovery.
Understanding First-in-Class Innovation
First-in-class drugs are therapies that target a novel biological mechanism not previously addressed by existing medicines. They introduce entirely new modes of action and often redefine standards of care.
Key characteristics of first-in-class drugs include
- Targeting previously unvalidated or newly discovered biological pathways
- High scientific uncertainty and elevated development risk
- Strong intellectual property positioning
- Potential to transform treatment paradigms
- Often receiving significant regulatory attention and priority review
First-in-class innovation is often viewed as the pinnacle of scientific achievement. These therapies can create entirely new therapeutic categories and establish companies as pioneers in a specific disease area. However, the scientific novelty also means higher attrition rates, unpredictable safety outcomes, and substantial investment requirements.
Defining Best-in-Class Strategy
Best-in-class drugs, in contrast, are designed to improve upon an existing therapeutic mechanism. They may offer better efficacy, improved safety profiles, enhanced dosing convenience, or superior pharmacokinetics compared to earlier drugs in the same class.
Best-in-class strategies typically focus on:
- Optimising already validated biological targets
- Reducing clinical and regulatory risk
- Enhancing patient compliance through improved formulations
- Offering competitive advantages in crowded markets
- Delivering incremental but meaningful therapeutic improvements
While often perceived as less groundbreaking, best-in-class drugs can generate significant commercial success. In many therapeutic areas, improved safety or superior tolerability can shift prescribing patterns dramatically.
Risk vs Reward: The Strategic Trade-Off
The core difference between first-in-class and best-in-class development lies in balancing risk and reward. Companies must evaluate whether they aim to redefine a disease area or compete within it.
First-in-Class Development Involves
- High research and validation costs
- Uncertain biological mechanisms
- Longer development timelines
- Greater potential for market exclusivity
- Breakthrough designation opportunities
Best-in-Class Development Offers
- Lower scientific uncertainty
- Established clinical endpoints
- Predictable regulatory pathways
- Faster market entry
- Competitive but crowded landscapes
Companies must evaluate whether they aim to redefine a disease area or compete within it. This decision influences portfolio diversification, investor expectations, and long-term corporate strategy.
Regulatory and Market Dynamics
Regulatory agencies play a crucial role in shaping innovation incentives.
For First-in-Class Therapies
- Regulators may provide expedited pathways
- Breakthrough therapy designation is more likely
- Higher scrutiny of safety and mechanism validation
- Post-marketing surveillance requirements may be stricter
For Best-in-Class Drugs
- Clinical trial designs are often more standardised
- Comparative studies against existing therapies are essential
- Market differentiation becomes critical
- Pricing pressures can be more intense
Market access strategies also differ. First-in-class therapies may command premium pricing due to novelty, while best-in-class drugs must demonstrate measurable superiority to justify competitive positioning.
The Role of Scientific Advancements
Modern technologies are influencing both strategies.
Technological Drivers Enabling First-in-Class Discovery Include
- Advanced genomics and biomarker identification
- Artificial intelligence-driven target discovery
- Multi-omics integration
- Systems biology approaches
Technologies Supporting Best-in-Class Optimisation Include
- Structure-based drug design
- Improved formulation science
- Enhanced delivery systems
- Predictive toxicology modelling
Innovation today is not limited to discovering new targets; it also involves refining and enhancing existing therapeutic classes.
Portfolio Diversification in Modern Pharma
Leading pharmaceutical companies increasingly adopt hybrid strategies that combine both innovation models.
Balanced portfolio strategies often include:
- High-risk first-in-class programs for transformative impact
- Lower-risk best-in-class programs for steady revenue generation
- Strategic partnerships to share development risk
- Platform technologies supporting multiple candidates
- Therapeutic area specialisation for competitive strength
This diversified approach allows companies to sustain innovation while managing financial exposure.
Investor and Commercial Considerations
The investment community closely evaluates innovation strategies.
Investors typically assess:
- Probability of technical success
- Time to market
- Competitive differentiation
- Intellectual property strength
- Long-term market sustainability
First-in-class projects may attract high-risk, high-reward investment interest, while best-in-class programs often appeal to those seeking predictable returns. The strategic positioning of a company’s pipeline can significantly influence valuation and funding access.
Patient Impact and Clinical Value
Ultimately, the debate must centre on patient outcomes.
First-in-Class Drugs May
- Offer solutions for previously untreatable conditions
- Introduce entirely new therapeutic options
- Address rare or underserved diseases
Best-in-Class Drugs May
- Improve safety and reduce side effects
- Enhance quality of life through better dosing schedules
- Increase treatment adherence
- Provide incremental but important improvements in survival or symptom control
From a healthcare system perspective, both forms of innovation are essential. Transformative breakthroughs and incremental improvements together drive progress in medicine.
Where is Drug Discovery Innovation Headed?
The future of drug discovery does not favour one strategy over the other—it increasingly demands strategic integration.
Emerging Trends Suggest:
- Greater use of precision medicine to validate first-in-class targets
- Increased competition within established therapeutic classes
- Hybrid molecules combining novel and optimised features
- Cross-industry collaborations to reduce discovery risk
- Data-driven decision-making guiding early pipeline strategy
Innovation is no longer defined solely by novelty but by measurable impact, sustainability, and scalability.
The choice between first-in-class and best-in-class development represents more than a scientific decision—it is a reflection of how pharmaceutical companies define innovation, manage risk, and pursue long-term impact. Both strategies play critical roles in shaping the global healthcare landscape.
At World BI, through the Drug Discovery Innovation Programme, we continue to examine these strategic shifts that determine the future of medicine. As the industry evolves, successful organisations will not simply choose between first and best they will strategically integrate both approaches to drive sustainable, meaningful innovation in drug discovery.